Product

Company

Clareo Health | SOLX Gold Shunt for Refractory Glaucoma

NCT01282346·17 sites·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

SOLX, Inc.

Age

21–any

Sex

ALL

Healthy volunteers

Not accepted

primary open-angle glaucoma
age 21 or over
refractory glaucoma, with IOP ≥ 24 mmHg on medications and failed prior incisional glaucoma surgery
detectable visual field defect (negative MD score)
written informed consent
available for up to 24 months follow-up

either eye with VA worse than count fingers
angle closure glaucoma episode within past 12 months
uveitic glaucoma, iridocorneal endothelial (ICE) syndrome, traumatic glaucoma, or neovascular glaucoma
diagnosis of pigmentary glaucoma or pseudoexfoliative glaucoma
other significant ocular disease, except cataract
active ocular infection
expected ocular surgery in next 12 months
no suitable quadrant for implant
systemic corticosteroid therapy \> 5 mg/day prednisone
intolerance to gonioscopy or other eye exams
mental impairment interfering with consent or compliance
pregnancy
known sensitivity to anticipated medications used at surgery
significant co-morbid disease
concurrent enrollment in another drug or device study

The record

StatusCompleted

PhaseNo phase

Taking part116

StartedJan 2011

UpdatedFeb 23, 2017

Conditions

Where17